|
Demographics of the study cohort and those with a medical or pharmacologic contraindication to mefloquine use, U.S. military personnel deployed to Afghanistan, 2007. |
||||
| Contraindication(s) to mefloquine |
||||
| Study cohort |
Medical |
Pharmacologic |
Either or Both |
|
|
|
||||
| Number (%) |
Number (%) |
Number (%) |
Number (%) |
|
| Total |
11725 (100) |
558 (100) |
837 (100) |
1127 (100) |
| Gender |
||||
| Male |
10614 (90.5) |
463 (83.0) |
670 (80.0) |
916 (81.3) |
| Female |
1111 (9.5) |
95 (17.0) |
167 (20.0) |
211 (18.7) |
| Race |
||||
| White |
8552 (72.9) |
428 (76.7) |
626 (74.8) |
846 (75.1) |
| Black |
1967 (16.8) |
84 (15.1) |
118 (14.1) |
171 (15.2) |
| Other |
1206 (10.3) |
46 (8.2) |
93 (11.1) |
110 (9.8) |
| Prior deployments |
||||
| 0 |
7119 (60.7) |
315 (56.5) |
494 (59.0) |
660 (58.6) |
| 1 |
3442 (29.4) |
175 (31.4) |
256 (30.6) |
347 (30.8) |
| 2+ |
1164 (9.9) |
68 (12.2) |
87 (10.4) |
120 (10.6) |
| Military specialty |
||||
| Combat |
2818 (24.0) |
112 (20.1) |
153 (18.3) |
214 (19.0) |
| Non-combat |
8907 (76.0) |
446 (79.9) |
684 (81.7) |
913 (81.0) |
| Age |
||||
| 18–19 |
521 (4.4) |
27 (4.8) |
18 (2.2) |
38 (3.4) |
| 20–29 |
7701 (65.7) |
356 (63.8) |
508 (60.7) |
702 (62.3) |
| 30–39 |
2774 (23.7) |
138 (24.7) |
240 (28.7) |
301 (26.7) |
| 40–49 |
688 (5.9) |
37 (6.6) |
66 (7.9) |
81 (7.2) |
| 50+ |
41 (0.3) |
0 (0.0) |
5 (0.6) |
5 (0.4) |
Nevin et al. Malaria Journal 2008 7:30 doi:10.1186/1475-2875-7-30 |
||||